TerminatedNo phase
The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin
Key facts
- Who runs it
- Aalborg University Hospital
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 1 Nov 2023
- Ended
- 29 Jul 2025
- Type of study
- Observational
- Record updated
- 21 April 2026
- Why it stopped
- Due to recruitment issues.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Diagnosis of type 2 diabetes for at least 1 year
- HbA1c of 53-75 mmol/mol at ???
- Treated with metformin for at least 1 year
- Can understand and read Danish
- Can use a smartphone, as well as the devices used in the clinical trial
- Signed informed consent
Who cannot take part
- Major surgery planned during the trial period
- Cancer diagnosis within five years prior to inclusion
- Cardiovascular disease or kidney disease which would indicate use of other second line treatments such as SGLT2 inhibitors or s.c. GLP1 receptor agonists (see also current guidelines https://endocrinology.dk/nbv/diabetes-melitus/behandling-og-kontrol-af-type-2-diabetes/)
- Other types of diabetes than type 2 diabetes
- Known allergy to semaglutide
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Conditions, which the investigators deem to render the participant unfit for inclusion in the trial, including a physical or cognitive inability to participate in the trial
- HbA1c value recorded less than 3 months prior to inclusion in trial
- Current or prior treatment with other glucose-lowering medications than metformin
- Participation in other trials
- Pregnancy or breastfeeding
- Known retinopathy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of the trial is to investigate the effect of adherence to oral semaglutide dosing instructions on glycaemic control in people with type 2 diabetes, which are dysregulated on metformin and naïve to second line antidiabetic treatment.
The group in the trial
- Study Cohort
People with dysregulated type 2 diabetes on metformin treatment, which are naïve to second line antidiabetic treatment. These participants will be started on oral semaglutide, as a second line antidiabetic treatment, in addition to their treatment with metformin. The participants will be started on 3mg and the dose increased according to the label. The oral semaglutide will be administered once daily.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin (DIACRON) - An Open-label Clinical Trial
- Publications
- Record updated
- 21 April 2026